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The majority of children with Down syndrome (DS) tend to have
frequent bacterial infections including recurrent respiratory infec-
tions. Our objective was to evaluate the production of antibodies to
pneumococcal polysaccharide antigens after active immunization in
DS subjects. IgG antibodies to pneumococcal serotypes (1, 3, 6B, 9V,
and 14) were measured before and 6 weeks after immunization with a
23-valent pneumococcal vaccine (Pneumo23®, Pasteur-Merrieux) in
6- to 13-year-old DS children (N = 17) and in aged-matched normal
controls (N = 30). An adequate response was defined as a 4-fold
increase over baseline or a post-immunization level of specific pneu-
mococcal serotype antibody ≥1.3 µg/mL. After immunization, all DS
children had an increase in post-immunization levels against all
serotypes analyzed. A 4-fold or more increase was observed in all DS
children concerning serotypes 1 and 14, in 90% of subjects for
serotypes 3 and 9V, and in 65% for serotype 6B. Regarding this
increase, 8 of the 17 DS children had an adequate response to all
serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 sero-
types. However, when we compared post-immunization levels be-
tween DS children and controls, we observed lower levels in the
former group (P < 0.05) for all serotypes except serotype 3. We
conclude that pneumococcal polysaccharide immunization could be
beneficial for these DS children.
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Down syndrome (DS) is the most com-
mon trisomy in liveborn children and the
major known genetic cause of mental retar-
dation (1). The incidence of DS in Latin
American countries is approximately 1/700
live births (2). Despite advancements in treat-
ment, pneumonia and other respiratory dis-
eases are still the major causes of morbidity
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and mortality in DS children (3). Different
aspects of the immune system have been
studied in DS to obtain a better understand-
ing of the increased risk of infection ob-
served in affected individuals (4). Abnor-
malities in humoral and cell-mediated im-
munities and in phagocytic function have
been reported (3-7).
Data concerning post-immunization anti-
body production in DS patients are variable.
Antibody production to tetanus toxoid and
influenza virus is decreased or normal (8,9),
and isohemagglutinin titers and natural anti-
bodies to Escherichia coli are normal (10).
The antibody response to bacteriophage rX174
is impaired both in primary and secondary
immunological responses (11). These facts
argue for an impaired humoral response in DS
patients. Polysaccharides are considered to be
T-independent antigens and immunization with
polysaccharide vaccines has been recom-
mended as a diagnostic tool to evaluate patient
ability to respond to those antigens (12). Nurmi
et al. (13) observed a lower response to polysac-
charide antigens in adult DS patients com-
pared to controls. In the present study, we
evaluated pneumococcal serotype antibodies
before and after immunization with a 23-va-
lent pneumococcal polysaccharide vaccine
(Pneumo23®) in DS children.
Subjects and Methods
Seventeen non-institutionalized 6- to 13-
year-old DS subjects attending a daily facil-
ity for mentally handicapped children (APAE-
Associação dos Pais e Amigos dos Excep-
cionais, São Paulo) were studied (10 girls
and 7 boys). None of them had a history of
recurrent infections or cardiovascular mal-
formations. Thirty age-matched healthy chil-
dren living in the same area of São Paulo
served as controls. All children were submit-
ted to clinical examination and peripheral
blood samples were obtained from each pa-
tient to quantify the levels of immunoglobu-
lin (Ig; G, A, M), of IgG subclasses and of
antibodies against polysaccharide pneumo-
coccal serotypes 1, 3, 6B, 9V, and 14.
Anti-pneumococcal IgG antibodies against
pneumococcal serotypes 1, 3, 6B, 9V, and
14 were determined using a modified ELISA
protocol (14,15). Standard, control and DS
children’s serum samples were pre-absorbed
for 30 min at 37ºC with Streptococcus pneu-
moniae C-polysaccharide (500 µg/mL in
undiluted serum; Statens Serum Institut,
Copenhagen, Denmark). The serotype-spe-
cific IgG antibody concentration (µg/mL)
was calculated using a standard curve ob-
tained for a serum pool that had been previ-
ously calibrated using the FDA 89-SF refer-
ence sample (CBER, U.S. Food and Drug
Administration, Rockville, MD, USA).
Serum samples were collected before and
6 weeks after immunization with the 23-
valent pneumococcal capsular polysaccha-
ride vaccine (Pneumo23® Pasteur-Merrieux,
Marcyl Etoile, Lyon, France). An adequate
response to individual polysaccharide was
arbitrarily defined as a post-immunization
antibody concentration equal to or higher
than 1.3 µg/mL or a minimum 4-fold in-
crease over the baseline value (14,15).
The Wilcoxon test was applied to com-
pare pre- and post-IgG anti-pneumococcal
serotype levels in DS patients, and the Mann-
Whitney test was used to compare these
antibodies between DS children and con-
trols. The study was approved by APAE and
by the UNIFESP-EPM Ethics Committee.
The parents of the children participating in
the study gave a written informed consent.
Results
Normal serum IgA and IgM levels were
observed in DS children. Compared to normal
values, all DS children but one had a serum
IgG level above the 97th percentile, and 8/17
of them had IgG levels higher than 2,000 mg/
dL. DS children showed a tendency to higher
levels of serum IgG1 and IgG3 compared to
controls. In 13 of 17 and in 12 of 17 DS
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children, IgG1 and IgG3 levels were higher
than the 97th percentile, respectively. In con-
trast, serum IgG2 levels below the 50th per-
centile were observed in 15/17 (88%) sub-
jects. Two DS children had serum IgG2 levels
below the 3rd percentile associated with IgG4
deficiency and they did not have any recurrent
infections. Almost 53% of DS children had
undetectable serum IgG4 levels.
Compared to controls, pre-immunization
antibody levels to pneumococcus were sig-
nificantly lower in DS children for all sero-
types evaluated and both groups showed a
significant increase of post-immunization
compared with pre-immunization levels
(Table 1). A 4-fold or more increase was
observed in all subjects for serotypes 1 and
14, in 90% of subjects for serotypes 3 and
9V, and in 65% for serotype 6B. Controls
had an adequate production of antibodies to
all serotypes. The mean increase (post/pre-
ratio) of IgG anti-pneumococcal serotype anti-
bodies was higher than 7 for DS children,
except for serotype 3 (Table 1, Figure 1). On
Figure 1. Comparison of the in-
crease of antibody levels after
immunization (Pneumo23®) for
serotypes 1, 3, 6B, 9V, and 14
in Down syndrome children (N
= 17) and controls (N = 30). The
numbers next to the symbols
refer to the individual increase.
Statistical comparisons are
given in Table 1.
Table 1. Mean pre- and post-immunization (Pneumo23®) antibody levels and post/
pre-ratio in children with Down syndrome (N = 17) and age-matched controls (N = 30).
Down syndrome Controls
Serotype Pre- Post- Post/pre- Pre- Post- Post/pre-
ratio ratio
1 GM 0.20 1.54* 10.9** 1.20 2.91*+ 2.4
95% CI 0.13-0.54 1.35-2.87 0.72-4.98 2.64-7.19
3 GM 0.66 1.94* 3.7** 1.49 1.98* 1.3
95% CI 0.42-1.99 1.65-2.86 1.46-2.87 1.92-3.31
6B GM 0.25 1.29* 8.9** 1.71 4.38*+ 2.6
95% CI 0.17-0.57 0.82-3.78 1.73-5.1 3.79-15.4
9V GM 0.17 1.28* 9.9** 1.00 2.66*+ 2.7
95% CI 0.12-0.4 0.84-2.95 0.68-3.46 2.42-5.68
14 GM 0.78 3.53* 7.3** 2.01 9.54*+ 4.7
95% CI 0.65-1.87 1.93-12.8 2.16-4.29 6.9-37.84
Data are reported as means and range. GM = geometric mean; 95% CI = 95%
confidence interval.
*P < 0.001 = post > pre. **P < 0.001 = Down syndrome > controls post/pre-ratio Down
syndrome vs control. +P < 0.05 = post-control > post-Down syndrome (Wilcoxon and
Mann-Whitney tests).
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the basis of the increase, eight of the 17 DS
children had an adequate response to all
serotypes analyzed, 8/17 patients to 4 sero-
types and 1/17 to 3 serotypes. However,
when we compared post-immunization lev-
els between DS children and controls, we
observed lower levels in the former group
(P < 0.05) to all serotypes except serotype 3
(Table 1). No DS child had levels of anti-
pneumococcal IgG equal to or higher than
1.3 µg/mL for serotypes 1 and 9 pre- or post-
immunization. Three DS children presented
levels equal to or higher than 1.3 µg/mL for
serotype 3, 1/17 DS children for serotype
6B, and 6/17 DS children for serotype 14.
DS children showed a significantly el-
evated post/pre ratio compared to controls
(Table 1). Two DS children with IgG2 defi-
ciency had an appropriate response to the
23-valent pneumococcal polysaccharide vac-
cine.
Discussion
It is well recognized that DS children
have increased susceptibility to infections,
mainly respiratory ones. They also have an
increased risk of leukemias and other malig-
nancies, as well as a higher incidence of
auto-antibodies. A number of immunologic
abnormalities have been noted in DS chil-
dren although most of them have no clear
immune dysfunction (3-5). Pneumococcal
vaccines have been recommended to groups
of patients who are at high risk, or who
experience severe or frequent diseases (16).
Increased serum IgG levels and decreased
IgM levels have been reported in DS chil-
dren in late childhood and adolescence (6),
as well as an increase of these immuno-
globulins in saliva (17). Our DS children had
increased serum IgG levels compared to con-
trols, reflecting an overstimulation of B lym-
phocytes mainly due to IgG1 and IgG3 iso-
types since these levels were elevated in the
majority of DS children. High serum levels
of IgG1 and IgG3 have been reported in DS
adults (18). Despite their high IgG levels,
DS children have been recently shown to
present a lower number of B lymphocytes
compared to controls throughout childhood
(19).
In adults, anti-polysaccharide antibodies
are found mainly with IgM and IgG2 iso-
types (20). A normal IgM level and a ten-
dency to lower levels of IgG2 were observed
in our DS children, in agreement with other
reports (18). Two DS children, aged 8 and
10 years, had serum IgG2 levels below the
3rd percentile but showed an adequate in-
crease of pneumococcal antibodies after im-
munization. Subnormal serum IgG2 levels
do not necessarily reflect a functional immu-
nodeficiency (21,22). An adequate response
to pneumococcal antigens depends on an
interaction between innate and adaptive im-
mune responses. An inefficient release of
mature T cells from the DS thymus to the
spleen leads to decreased education of B
cells by T cells which could explain the
diminished antibody responses of DS B cells
to bacterial and viral antigens (4). However,
polysaccharide antigens are considered to
be thymus-independent and repeated epi-
topes expressed by polysaccharides induce
multivalent membrane immunoglobulin cross-
linking on the B-cell surface resulting in
activation and proliferation of theses cells
(23).
A normal IgG antibody response to pneu-
mococcal immunization has not been well
defined but a 2- to 4-fold rise in antibody
levels post-immunization generally reflects
an adequate response. Several other vari-
ables should also be considered, i.e., the
protective level may depend on the age of
the individual and may differ for different
pneumococcal serotypes (24-26). There is a
delay in the ontogeny of the acquisition of
the polysaccharide antigen response, which
involves very poor immunogens for infants
(27,28). A specific antibody response to
polysaccharide antigens is complete in chil-
dren over 2 years of age (24,29). Our DS
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children were older than 5 years and had a
significant increase in the levels of anti-
bodies to all serotypes evaluated after im-
munization, although these levels were lower
than those observed in controls. In spite of
lower levels compared to normal controls,
DS children showed a 7-fold mean increase
in antibodies which suggests that they pro-
duced pneumococcal antibodies after im-
munization and that probably this vaccine
could offer some protection for them.
In Brazil, the most prevalent pneumo-
coccal serotypes isolated from invasive in-
fections are 1, 5, 6, and 14 (30,31) and the
serotype distribution for invasive pneumo-
coccal diseases is age-related (32). Pre-im-
munization levels of serotype 14 antibody
were higher than 1.3 µg/mL in 6/17 of our
DS children, suggesting previous contact.
However, the other serotypes were observed
in only a few patients and their mean levels
were significantly lower than those of nor-
mal controls. It was presumed that the DS
children and normal controls were exposed
to the same pneumococcal serotypes be-
cause they lived in the same city and were of
similar socioeconomic status. Similar results
were observed by others in DS adults and
controls living in the same area (13).
The CDC’s Advisory Committee on Im-
munization Practices (ACIP) had previously
recommended 23-valent pneumococcal poly-
saccharide vaccines for use among children
over 2 years of age who had a high risk of
pneumococcal disease, including those with
chronic underlying diseases or who were
immunocompromised. Today the ACIP rec-
ommends the new 7-valent pneumococcal
conjugate vaccine (33). Although the conju-
gate vaccine has many advantages, it is very
expensive and includes only 7 serotypes.
Serotypes 1 and 5, which are not present in
this vaccine, remain among the principal
serotypes in Brazil, mainly in children with
pneumonia (32). The polysaccharide vac-
cine may be an alternative for these patients
over 2 years old in developing countries.
We conclude that DS children present an
adequate increase of antibody levels after
the pneumococcal polysaccharide vaccine
and that they could derive some benefit from
this vaccine.
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